This removes the financial penalty for dose optimization, meaning you can reach your ideal dose faster without budget constraints limiting medical progress
This neurobiological change helps explain why patients find it easier to adhere to reduced-calorie diets while taking these medications
August 2023: A Louisiana woman named Jaclyn Bjorklund filed a lawsuit against Novo Nordisk and Eli Lilly after experiencing gastrointestinal (GI) side effects, including gastroparesis or stomach paralysis
Quieter Cravings, Easier Choices Calms the "food noise": It gently turns down the constant, loud hunger signals in your brain, making it easy to listen to your body
Novo Nordisk, maker of the glucagon-like peptide-1 (GLP-1) agonist medication semaglutide (Wegovy), recently received accelerated approval from the U.S
Novos next-generation answer, CagriSema, trailed Zepbound in a head-to-head trial that missed its primary endpoint, leaving the Danish firm to consolidate around semaglutide after cutting roughly 9,000 jobs and warning of a weaker 2026
